Krystal Biotech Inc expected to post a loss of 38 cents a share - Earnings Preview

Krystal Biotech

23/02/2024 14:08

* Krystal Biotech Inc  KRYS.OQ   KRYS.O  is expected to show
a
rise in quarterly revenue when it reports  results on February
26 for the period ending December 31 2023
    * The Pittsburgh Pennsylvania-based  company is expected to
report
revenue of $28.607 million, according to the mean estimate from
9 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Krystal Biotech Inc is
for a
loss of 38 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Krystal
Biotech
Inc is $156.50​, above​ its last closing price of $111.96. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.32       -0.29      -0.69     Missed  -141.3
 Jun. 30 2023  -0.69       -0.74      -1.25     Missed  -69.7
 Mar. 31 2023  -1.43       -1.44      -1.76     Missed  -22.3​
 Dec. 31 2022  -1.31       -1.32      -1.25     Beat    5.4
 ​​Sep.        -1.23       -1.22      -1.17     Beat    3.9
 30 2022                                                
 Jun. 30 2022  -0.99       -1.02      -1.10     Missed  -8.3​
 Mar. 31 2022  -1.06       -1.05      -0.99     Beat    5.6
 Dec. 31 2021  -0.75       -0.73      -0.95     Missed  -29.7
 This summary was machine generated February 23 at 14:07 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)